Role of Glucagon in Automated Insulin Delivery.

Leah M Wilson, Peter G Jacobs, Jessica R Castle

Journal: Endocrinology and metabolism clinics of North America 2021;49(1):179-202

PMID: 31980117

Free Full Text on PubMed Central View on PubMed

Abstract

Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous. Automated insulin delivery systems can improve glucose control while reducing burden for people with diabetes. One approach to improve treatment outcomes is to incorporate the counter-regulatory hormone glucagon into the automated delivery system to help prevent the hypoglycemia that can be induced by the slow pharmacodynamics of insulin action. This article explores the advantages and disadvantages of incorporating glucagon into dual-hormone automated hormone delivery systems.

Address: Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Harold Schnitzer Diabetes Health Center, 3181 Southwest Sam Jackson Park Road, L607, Portland, OR 97239-3098, USA. Electronic address: [email protected].; Department of Biomedical Engineering, Oregon Health & Science University, Mail Code: CH13B, 3303 Southwest Bond Avenue, Portland, OR 97239, USA.; Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Harold Schnitzer Diabetes Health Center, 3181 Southwest Sam Jackson Park Road, L607, Portland, OR 97239-3098, USA.

DOI: 10.1016/j.ecl.2019.10.008

Link outs

Free resources

Full Text Sources:

Medical:

Subscription / membership required

Full Text Sources:

MeSH Terms: Automation, Diabetes Mellitus, Type 1, Drug Therapy, Combination, Glucagon, Glycemic Control, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Pancreas, Artificial